Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 21, 2025Open Access

SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJohn T. PhoenixABAudris BudreikaDSDevin A Schmeck

Discussion

Loading...

Member takes

Overview

Research reveals SOX2 engages FOXA1 to enhance resistance in prostate cancer, suggesting a new therapeutic approach.

Key Points

  • MAIN FINDING: SOX2 and FOXA1 work together to promote cell cycle progression in therapy-resistant prostate cancer.
  • KEY EVIDENCE: Their interaction aids in lineage plasticity, contributing to the aggressive neuroendocrine prostate cancer subtype.
  • APPROACH: The study investigates the physical binding and regulatory role of these transcription factors in advanced prostate cancers.
  • SIGNIFICANCE: Targeting the SOX2/FOXA1 partnership may offer innovative treatments for patients with late-stage prostate cancer.

Cite This Study

Phoenix et al. (2025) studied this question.

synapsesocial.com/papers/689a02c9e6551bb0af8cd024https://doi.org/10.1101/2025.07.18.664790
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting FOXA1 and FOXA2 Disrupts the Lineage-Specific Oncogenic Output Program in Prostate Cancer2025
  2. 2FOXA2 and NKX2-1 Orchestrate Neuroendocrine Lineage Plasticity in Prostate Cancer2025
  3. 3Mapping the FOXA1 Interactome in ER+ Breast Cancer Cells using Proximity Labeling Reveals Novel Interactions with the Orphan Nuclear Receptor NR2C22025
  4. 4SOX4-Mediated Post-Transcriptional suppression of PTEN via miR-106b~25 Cluster Contributes to Prostate Cancer Aggressiveness.2025
  5. 5Epigenetic De-repression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression2025 · 8 citations